Litcius/Paper detail

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial

Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Bécourt, Nicolas Delanoy, Florence Joly, Alain Lortholary, Benoît You, P. Bouchaert, Emmanuelle Malaurie, Sébastien Gouy, Marie‐Christine Kaminsky, Jérôme Meunier, Jérôme Alexandre, Dominique Berton, Nadine Dohollou, Coraline Dubot, Anne Floquet, Laure Favier, Laurence Venat‐Bouvet, Michel Fabbro, Christophe Louvet, Jean‐Pierre Lotz, Sophie Abadie‐Lacourtoisie, Christophe Desauw, Francesco Del Piano, Marianne Leheurteur, Nathalie Bonichon-Lamichhane, Mansour Rastkhah, Philippe Follana, Justine Gantzer, Isabelle Ray‐Coquard, Éric Pujade-Lauraine

2023Gynecologic Oncology27 citationsDOI

Topics & Concepts

MedicineNintedanibHazard ratioCarboplatinInternal medicinePlaceboDebulkingChemotherapyClinical endpointOncologyUrologySurgeryOvarian cancerRandomized controlled trialGastroenterologyCancerConfidence intervalPathologyIdiopathic pulmonary fibrosisCisplatinLungAlternative medicineOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyHER2/EGFR in Cancer Research